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ABSTRACT
Porphyrias form a heterogeneous group of 
disorders of haem biosynthesis. They are 
often missed or wrongly diagnosed in the 
emergency department. Acute porphyrias 
present most commonly as abdominal 
pain or as neurological or atypical psy-
chiatric symptoms. The variety of clinical 
features may delay diagnosis, and unrec-
ognized disease is potentially life-threaten-
ing. The frequency and severity of attacks 
vary widely. In some people, this disease 
remains latent throughout life, even in the 
presence of precipitating factors. Other 
people experience frequent and sometimes 
life-threatening attacks even in the appar-
ent absence of exogenous precipitating fac-
tors.
Laboratory diagnosis of acute porphyria 
includes porphyrin precursors delta ami-
nolevulic acid and porphobilinogen. Pa-
tients presenting with acute crises often 
have several-fold increases in PBG above 
the reference interval, usually > 10 times 
the upper reference limit. Hyponatremia 
and rabdomyolysis are relatively common 
manifestation accompanying acute attack. 
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INTRODUCTION
Porphyrias are a group of metabolic dis-
eases caused by defect in one of the seven 
enzymes involved in the haem biosynthe-
sis pathway (figure 1). They form a het-
erogeneous group of disorders of haem 
biosynthesis, and they are often missed or 
wrongly diagnosed. Partial deficiency of 
one of the seven enzymes in the pathway 
causes characteristic clinical and biochem-
ical features. These disorders are due to a 
specific alteration in the pattern of accu-
mulation of porphyrin and porphyrin pre-
cursors. Each type of porphyria is defined 
by a unique pattern of accumulation and 
excretion of haem precursors, as well as a 
reduction in the relevant enzyme activity. 
A correct interpretation of the appropriate 
biochemical investigation is essential to ac-
curately diagnose and manage porphyrias, 
as clinical features alone are not sufficiently 
specific to either confirm the diagnosis or 
to distinguish between the various forms.
Porphyrias are classified on the clinical 
basis into acute porphyrias (character-
ized by neuropsychiatric symptoms) or 
cutaneous porphyrias (characterized by 
photosensitivity to sunlight). Porphyrias 
are also classified as erythropoietic por-
phyria or hepatic porphyrias, depending 
on whether the genetic defect mainly af-
fects the erythroid or the hepatic haem 
biosynthesis. There are four acute hepatic 
porphyrias characterized by neurologic 
and potentially life-threatening acute at-
tacks: acute intermittent porphyria (AIP), 
variegate porphyria (VP), hereditary co-
proporphyria (HCP) and 5-aminolevulinic 
dehydratase deficiency porphyria (ALAD-
deficiency porphyria). The symptoms of 
AIP and ALAD-deficiency porphyria are 
essentially neurological, whereas VP and 
HCP are mixed forms which may present 
with either neurovisceral manifestations 
or cutaneous photosensitivity or both. AIP 
is the most commonly encountered acute 
porphyria worldwide and has a higher 
clinical penetrance compared with AP 
and HCP. ALAD deficiency porphyria is 
extremely rare and inherited in recessive 
form. Acute hepatic porphyria is char-
acterized by acute neuropsychiatric and 
potentially life-threatening attacks pre-
cipitated by endogenous or environmental 
factors such as reproductive hormones, 
fasting, stress, infection or porphyrino-
genic drugs and alcohol – that is, factors 
increasing the requirements for hepatic 
haem biosynthesis. The onset of symp-
toms almost never occur before puberty, 
and women of fertile age are more affected 
than men, implying special susceptibility 
to reproductive hormones. AIP may serve 
as a general model for the clinical manage-
ment of acute porphyria crises, since treat-
ment, diagnostic and preventive meas-
ures are similar in all acute porphyrias. 
Figure 1. Haem synthesis: metabolites, 
enzymes and disorders associated with en-
zyme deficiencies.
CLINICAL MANIFESTATION OF ACUTE 
INTERMITTENT PORPHYRIA ATTACK
Acute attacks are often triggered by expo-
sure to exogenous participating factors, 
including a wide range of commonly pre-
scribed drugs. The frequency and severity 
of attacks vary widely and are rare before 
puberty. They are most common in people 
in their thirties and are four to five times 
more common in females than in males, 
with a peak age of presentation in the early 
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30s. 
In some people the disease remains latent 
throughout life, even in the presence of 
precipitating factors. Other people experi-
ence frequent and sometimes life-threat-
ening attacks even in the apparent absence 
of exogenous precipitating factors.
The manifestation of acute porphyria at-
tacks are mainly neurological and ac-
companied by metabolic manifestation. 
The variety of clinical features may delay 
diagnosis, and unrecognized the disease 
is potentially life-threatening. The most 
common symptom is severe abdominal 
pain without peritoneal signs, present in 
over 90% of patients. Hypertension and 
tachycardia are generally present. Hypona-
tremia may take place due to sodium loss, 
overhydration or hypothalamic involve-
ment. Seizures can be a consequence of 
hyponatremia or hypomagnesemia, or 
be secondary to CNS involvement. Other 
general symptoms often accompanying 
acute attacks are tiredness, restlessness 
and headaches. Patients must be evaluated 
clinically to exclude other causative clini-
cal conditions.
LABORATORY DIAGNOSIS OF ACUTE 
INTERMITTENT PORPHYRIA
The porphyrin precursors delta aminole-
vulic acid (ALA) and PBG are invariably 
increased when neuropsychiatric illness is 
caused by AIP. Urine is usually coloured 
red-brown on standing due to PBG oxi-
dation into porphobilin. Urine discolora-
tion is a trait described in a large number 
of case reports as a feature leading to AIP 
diagnosis. The expected colour-based di-
agnosis may be absent in patients with 
ongoing fluid administration or increased 
urinary frequency.  
Laboratory qualitative screening test to 
confirm the presence of PBG should be 
available in an acute clinical laboratory. 
False-negative and false-positive results are 
not uncommon, and if a result is uncertain 
the semiquantitative test should be avail-
able. Screening test should be followed by 
quantitative analysis of ALA and PBG. 
Urine ALA and PBG are measured by ion 
exchange chromatography and plasma de-
termined by the HPLC-mass spectrometry 
method. The ratio may be important in the 
AIP surveillance program, as an increasing 
ratio may indicate impaired renal function. 
The ratio of PBG and ALA in urine (mmol/
mol creatinine) or plasma (µmol/L) is ap-
proximately 0.3 in healthy individuals and 
in latent AIP carriers. In AIP patients with 
chronic high excretion, the ratio is approx-
imately 2.0.
Only a few carriers present high concentra-
tions of ALA and PBG secondary to 50% 
a PBGD activity. Some display an asymp-
tomatic clinical pattern, while others may 
present with acute or sub-acute chronic 
symptoms. Patients presenting with acute 
crises often have several-fold increases in 
PBG above the reference interval, usually > 
10 times the upper reference limit.
AIP diagnosis must always, if possible, be 
followed by gene analysis.
Most hospital wards have packages of 
analyses applied in care for patients with 
porphyrias; general laboratory tests should 
include full blood status, liver and kidney 
function test and electrolytes. Recent stud-
ies have shown that the following tests to 
assess hepatic inflammation may be useful: 
C-reactive protein, clotting function and 
serum ferritin should be monitored during 
treatment.
HYPONATREMIA
Hyponatremia is a relatively common met-
abolic manifestation accompanying acute 
attack. It is usually mild and easily cor-
rected. It is proposed to be secondary to 
excessive loss due to vomiting, diarrhoea, 
sweating or increased renal loss due to os-
motic diuresis after glucose infusion and 
iatrogenic fluid substitute without electro-
lyte replacement. Hyponatremia can also 
be found on admission of acute attack pa-
tients without the proposed mechanisms, 
and antidiuretic hormone has also been 
suggested as a possible factor. Hypona-
tremia in AIP may cause seizures and en-
cephalopathy, while severe hyponatremia 
may lead to brain edema. Hyponatremia 
is found in a number of disorders of CNS, 
and thus AIP should be kept in mind as a 
differential diagnosis. In unknown carri-
ers, an overlapping of symptoms may delay 
AIP diagnosis. 
RHABDOMYOLYSIS
Rhabdomyolysis in AIP attacks is accom-
panied by important muscle waste and 
myoglobinuria, and is probably more com-
mon than the few reported cases in litera-
ture would suggest. The condition presents 
with important elevation of creatinine 
kinase (CK) levels, as well as AST, often 
concurrent with hyponatremia and other 
symptoms such as abdominal pain, vomit-
ing and muscle pain. The cause of rabdo-
myolysis in AIP is not clear
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